A Phase 3 interventional study of Iloperidone and Ziprasidone in Schizophrenia, sponsored by Vanda Pharmaceuticals. Completed at 42 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing iloperidone in Schizophrenia — 2 open to participants now, 2 under way, 1 of them phase 3. iloperidone · Schizophrenia.
Among the 11 studies testing iloperidone in Schizophrenia, this one is the 2nd largest by enrollment, is the only one that started in 2005, is one of 4 in phase 3, and was the 1st registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →2 of the 11 studies testing iloperidone in Schizophrenia are open now, in 1 country. Recruiting first, the newest first:
Vanda Pharmaceuticals · Sites in United States
Ages 18–65
Vanda Pharmaceuticals · Sites in United States
Ages 12–17
By country, each count listing its studies:
iloperidone: first FDA approval 2009 (FANAPT). What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2005.
This study's enrollment of 593 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 260 across the 11 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 5 most frequent:
Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.
Vanda Pharmaceuticals has 8 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
1 of the studies testing iloperidone in Schizophrenia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06961968Phase 3Vanda PharmaceuticalsRandomized Withdrawal Study in Patients With Schizophrenia | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing iloperidone in Schizophrenia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.
Schizophrenia is a severe mental illness affecting an estimated 1% of the world's population. Patients with schizophrenia suffer from productive symptoms (e.g., hallucinations and delusions), and deficit symptoms (e.g., a reduction or absence of normal behaviors or emotions). Other symptoms include a reduced ability to recall and learn new information.
Iloperidone is being development as a treatment for symptoms of schizophrenia. This trial will test the safety and efficacy of iloperidone in patients with an acute exacerbation of the disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral iloperidone
Drug: Iloperidone
Oral ziprasidone
Drug: Ziprasidone
Oral placebo
Drug: Placebo
Also known as: Fanapt®, VYV-683
Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score
The PANSS is a 30-item scale developed to assess the severity of symptoms of schizophrenia. The PANSS items are divided into positive, negative, and general psychopathology factors. Items are rated on a scale of 1 (absent) to 7 (extremely severe). The PANSS-T score is the sum of scores for all 30 PANSS items (i.e., the sum of the three subscales), with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms. A negative change from baseline indicates improvement.
Time frame: 4 weeks
| Milestone | Iloperidone | Ziprasidone | Placebo |
|---|---|---|---|
| Started | 295 | 149 | 149 |
| Safety population | 300 | 150 | 147 |
| Completed | 193 | 98 | 90 |
| Not completed | 102 | 51 | 59 |
The PANSS is a 30-item scale developed to assess the severity of symptoms of schizophrenia. The PANSS items are divided into positive, negative, and general psychopathology factors. Items are rated on a scale of 1 (absent) to 7 (extremely severe). The PANSS-T score is the sum of scores for all 30 PANSS items (i.e., the sum of the three subscales), with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms. A negative change from baseline indicates improvement.
| score on a scale | Iloperidone | Ziprasidone | Placebo |
|---|---|---|---|
| Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score | -12.0 ± 1.03 | -12.3 ± 1.44 | -7.1 ± 1.48 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Iloperidone | 0/300 (0%) | 2/300 (0.7%) | 221/300 (73.7%) |
| Ziprasidone | 0/150 (0%) | 2/150 (1.3%) | 118/150 (78.7%) |
| Placebo | 0/147 (0%) | 5/147 (3.4%) | 86/147 (58.5%) |
| Event | Iloperidone | Ziprasidone | Placebo |
|---|---|---|---|
| ConvulsionNervous system disorders | 0/300 | 0/150 | 2/147 |
| Psychotic disorderPsychiatric disorders | 1/300 | 2/150 | 0/147 |
| BradycardiaCardiac disorders | 0/300 | 0/150 | 1/147 |
| Chest painGeneral disorders | 0/300 | 0/150 | 1/147 |
| Myocardial infarctionCardiac disorders | 0/300 | 0/150 | 1/147 |
| HyponatremiaMetabolism and nutrition disorders | 0/300 | 0/150 | 1/147 |
| SchizophreniaPsychiatric disorders | 0/300 | 0/150 | 1/147 |
| Microcytic anemiaBlood and lymphatic system disorders | 1/300 | 0/150 | 0/147 |
| Event | Iloperidone | Ziprasidone | Placebo |
|---|---|---|---|
| SedationNervous system disorders | 38/300 | 41/150 | 12/147 |
| HeadacheNervous system disorders | 61/300 | 35/150 | 29/147 |
| DizzinessNervous system disorders | 51/300 | 20/150 | 11/147 |
| NauseaGastrointestinal disorders | 29/300 | 21/150 | 13/147 |
| Weight increasedInvestigations | 34/300 | 7/150 | 3/147 |
| VomitingGastrointestinal disorders | 17/300 | 16/150 | 10/147 |
| DyspepsiaGastrointestinal disorders | 24/300 | 15/150 | 15/147 |
| ConstipationGastrointestinal disorders | 27/300 | 12/150 | 14/147 |
| TachycardiaCardiac disorders | 28/300 | 3/150 | 1/147 |
| Extrapyramidal disorderNervous system disorders | 10/300 | 14/150 | 3/147 |
| Age, Continuous(years) | Iloperidone | Ziprasidone | Placebo | Total |
|---|---|---|---|---|
| Mean | 39.5 ± 10.4 | 40.0 ± 9.9 | 40.7 ± 10.4 | 39.9 ± 10.3 |
| Sex: Female, Male(Participants) | Iloperidone | Ziprasidone | Placebo | Total |
|---|---|---|---|---|
| Female | 50 | 36 | 35 | 121 |
| Male | 245 | 113 | 114 | 472 |
| Race/Ethnicity, Customized(Participants) | Iloperidone | Ziprasidone | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaskan Native | 2 | 0 | 1 | 3 |
| Asian | 25 | 12 | 15 | 52 |
| Black or African American | 147 | 76 | 76 | 299 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 0 | 2 |
| White | 111 | 51 | 46 | 208 |
| Other | 8 | 10 | 11 | 29 |
Ran from Nov 2005 to primary completion in Sep 2006, 10 months.
Results were first posted in Dec 2024, 18 years 2 months after primary completion.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 10 months is below that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iloperidone